$11 million in proceeds expected to be received during 2026, with remainder of expected proceeds to be received in future revenue earnouts Vivasure Medical Limited (“Vivasure”) has been a strategic ...
Precision BioSciences, Inc. , a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today ...
Sensorineural hearing loss (SNHL) is a highly prevalent sensory disorder globally, affecting over 1.5 billion people, with a ...
Two NDA submissions expected by mid-February 2026 for ulixacaltamide in essential tremor and relutrigine in SCN2A/8A-DEEs, both with Breakthrough ...
Detailed price information for Compass Therapeutics Inc (CMPX-Q) from The Globe and Mail including charting and trades.
Detailed price information for Compass Therapeutics Inc (CMPX-Q) from The Globe and Mail including charting and trades.
Nanomaterials, Energy Storage, Electrochemical Sensors, Sensing Technologies Share and Cite: Anney, A. and Biswas, S. (2026) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback